A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Inclusion Criteria:

1. Understood and signed an informed consent form. 2. Eastern Cooperative OncologyGroup (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months.

2. Histopathologically confirmed recurrent or metastatic advanced endometrialcancer.

3. Has at least one measurable lesion. 5. Agree to provide tumor tissue samplesfor MSI/MMR status detection. 6. Adequate laboratory indicators. 7. Serum orurine pregnancy tests are negative within 7 days before randomization; Men andwomen should agree to use effective contraception during the study period andafter the end of the study period within 6 months.

Exclusion Criteria:

• 1.Concomitant disease and medical history:

1. Has diagnosed and/or treated additional malignancy within 3 years prior torandomization;

2. Pathological diagnosed as uterine sarcoma;

3. Has multiple factors affecting oral medication;

4. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy.

5. Has received major surgical treatment, open biopsy and so on within 28 daysbefore the start of the study.

6. Has a unhealed wound or fracture for a long time;

7. Has cerebrovascular accident, deep vein thrombosis and pulmonary embolismwithin 6 months before the study;

8. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiringrecurrent drainage procedures;

9. Has a history of psychotropic substance abuse and unable to quit or mentaldisorders;

10. Has any serious and / or uncontrolled disease; 2. Tumor-related symptoms andtreatment:

11. Has received surgery, chemotherapy, radiotherapy or other anticancer therapywithin 4 weeks before the start of the study;

12. Has received proprietary Chinese medicine with anti-tumor indications in theNMPA approved drug instructions within 2 weeks before the start of the study;

13. Has received immunotherapeutic drugs against PD-1, PD-L1, CTLA-4 and otherrelated drugs;

14. Has used antiangiogenic drugs such as bevacizumab, anlotinib, apatinib,lenvatinib, sorafenib, Sunitinib, regorafenib, fruquintinib, etc;

15. Has received hormone therapy for endometrial cancer within a week before thefirst dose ;

16. CT or MRI showed that the tumor had invaded the important blood vessels;

17. Has symptomatic central nervous system (CNS) disease and/or cancerousmeningitis, pia mater disease; 3. Related to research and treatment:

18. Has received attenuated live vaccine within 28 days before randomization orplanned to received attenuated live vaccine during the study period.

19. Has a history of severe allergic diseases.

20. Has active autoimmune diseases requiring systemic treatment occurred within 2years before the study.

21. Has Participated in other clinical trials within 4 weeks before firstdose. 5. According to the judgement of the investigators, there are otherfactors that may lead to the termination of the study.